Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	9.99Cr 1.01Cr 88.53L 83.21L 75.93L 1.43Cr 97Cr 1.43Cr 3.85Cr 49Cr 3.8Cr 3.72Cr 159.44Cr	P/E 2026 *	-3x	P/E 2027 *	-2.49x
Enterprise Value	9.19Cr 93.19L 81.44L 76.54L 69.85L 1.31Cr 89Cr 1.31Cr 3.54Cr 45Cr 3.5Cr 3.42Cr 146.67Cr	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	52.67%	Yield 2026 *	-	Yield 2027 *	-

17/09	Vivesto sees tumor effect with Paccal Vet in cat study	FW
17/09	Vivesto reports positive topline results from the Paccal Vet feline study	FW
17/09	Vivesto Reports Positive Paccal Vet Cat Topline Results Supporting Continued Clinical Development	CI
15/09	Vivesto reports positive topline results in pilot dog study (update)	FW
15/09	Vivesto reports positive topline results in pilot dog study	FW
15/09	Vivesto AB Reports Positive Topline Results from Clinical Pilot Study Evaluating Paccal Vet in Dogs with Splenic Hemangiosarcoma Following Splenectomy	CI
13/08	Vivesto narrowed its loss in the second quarter, CEO says: we are staying on plan	FW
13/08	Vivesto AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
13/08	Calendar for Thursday, August 13	FW
07/07	Vivesto chairman Peter Zonabend increases his shareholding	FW
01/07	Vivesto Completes Enrollment in Cat Study of Paccal Vet	FW
01/07	Vivesto Completes Recruitment in Paccal Vet Dose-Finding Study in Cats and Determines Maximum Tolerated Dose	CI
26/06	Vivesto Completes Enrollment in Canine Study	FW

26/05	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
21/11	DNB Carnegie Lowers Target Value for Vivesto Following Rights Issue Announcement	FW
13/25/13	DNB Carnegie Lowers Target Value for Vivesto as Costs Expected to Remain Steady	FW
09/24/09	Paccal Vet analysis could raise the temperature for Vivesto - Penser	FW
30/22/30	Orrön Energy the year's best and Isofol Medical the year's worst share on Nasdaq Stockholm	FW

17/09	Vivesto: Positive top-line results in cat study	AQ
17/09	Vivesto reports positive Paccal Vet cat topline results supporting continued clinical development	AQ
15/09	Vivesto: Positive top-line results in dog study	AQ
15/09	Vivesto’s positive dog topline results support continued development and strengthen partnering prospects for Paccal Vet	AQ
13/08	Vivesto: Largely a non-event, key readouts ahead – Q2 review	AQ

25/20/25	Oasmia Pharmaceutical AB (publ) : un partenariat stratégique pour la distribution d'Apealea
30/20/30	Oasmia Pharmaceutical AB (publ) : Apealea arrive sur les marchés scandinaves

Oasmia Pharmaceutical AB Share Price NORDIC GROWTH MARKET

Stocks

OASM

SE0000722365

Pharmaceuticals

Valuation: Oasmia Pharmaceutical AB

Latest news: Oasmia Pharmaceutical AB

Last Transcript: Oasmia Pharmaceutical AB

Analysts' recommendations: Oasmia Pharmaceutical AB

Press Releases: Oasmia Pharmaceutical AB

News in other languages: Oasmia Pharmaceutical AB

Managers and Directors: Oasmia Pharmaceutical AB

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Erik Kinnman CEO	Chief Executive Officer	68	23/01/2023
Björn Svanström DFI	Director of Finance/CFO	55	01/07/2026
Teresa Fernandez Zafra CTO	Chief Tech/Sci/R&D Officer	39	01/01/2023

Director	Title	Age	Since
Isak Peter Zonabend CHM	Chairman	46	25/05/2022
Hege Hellstrom BRD	Director/Board Member	61	26/09/2019
Pål Ryfors BRD	Director/Board Member	43	25/05/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OASMIA PHARMACEUTICAL AB	-.--%	-.--%	-	-	1.02Cr
ELI LILLY AND COMPANY	+0.34%	+3.32%	+55.49%	+113.22%	1,03800Cr
JOHNSON & JOHNSON	+0.04%	+0.82%	+54.64%	+67.84%	65TCr
ABBVIE INC.	+0.39%	+0.86%	+19.19%	+73.70%	47TCr
ROCHE HOLDING AG	-0.19%	+0.97%	+34.30%	+45.99%	36TCr
NOVARTIS AG	+0.28%	+2.30%	+18.47%	+26.67%	27TCr
ASTRAZENECA PLC	+0.89%	+4.59%	+10.19%	+14.72%	26TCr
AMGEN INC.	+4.07%	+9.05%	+43.24%	+53.03%	21TCr
NOVO NORDISK A/S	-0.46%	-6.20%	-32.46%	-59.65%	18TCr
GILEAD SCIENCES, INC.	+1.36%	+4.50%	+35.91%	+103.81%	19TCr
Average	+0.68%	+1.04%	+26.55%	+48.82%	40.17TCr
Weighted average by Cap.	+0.53%	+1.47%	+36.52%	+67.36%

	2026 *	2027 *
Net sales	-	-
Net income	-3.1Cr -31.45L -27.48L -25.83L -23.57L -44.24L -30Cr -44.25L -1.2Cr -15Cr -1.18Cr -1.16Cr -49Cr	-4Cr -40.58L -35.46L -33.33L -30.41L -57.08L -39Cr -57.09L -1.54Cr -20Cr -1.52Cr -1.49Cr -64Cr
Net Debt	-80L -8L -7L -7L -6L -11.42L -7.76Cr -11.42L -30.87L -3.96Cr -30.48L -29.81L -13Cr	-1.7Cr -17.25L -15.07L -14.16L -12.93L -24.26L -16Cr -24.26L -65.6L -8.42Cr -64.76L -63.34L -27Cr